Avenue Therapeutics Inc.
| NASDAQ: ATXI | Healthcare / Biotechnology / USA |
| 1.05 | +0.0005 | +0.05% | Vol 89.30K | 1Y Perf -89.14% |
| Mar 24th, 2023 10:54 DELAYED |
| BID | 1.05 | ASK | 1.06 | ||
| Open | 1.05 | Previous Close | 1.05 | ||
| Pre-Market | 1.06 | After-Market | - | ||
| 0.01 0.95% | - - |
| Target Price | 9.00 | Analyst Rating | — 0.00 | |
| Potential % | 756.74 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.43 | Earnings Rating | Neutral | |
| Market Cap | 5.81M | Earnings Date | 24th Mar 2023 | |
| Alpha | -0.03 | Standard Deviation | 0.24 | |
| Beta | 1.00 |
Today's Price Range 1.031.09 | 52W Range 0.983016.65 | 5 Year PE Ratio Range -9.50-3.30 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -5.41% | ||
| 1 Month | -6.25% | ||
| 3 Months | -13.93% | ||
| 6 Months | -76.67% | ||
| 1 Year | -89.14% | ||
| 3 Years | -99.00% | ||
| 5 Years | -98.72% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -144.39 | |||
ROE last 12 Months | 5.78K | |||
ROA (5Y Avg) | -357.32 | |||
ROA last 12 Months | -870.59 | |||
ROC (5Y Avg) | -293.36 | |||
ROC last 12 Months | -847.42 | |||
Return on invested Capital Q | -237.21 | |||
Return on invested Capital Y | -55.55 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.30 | ||||
| 14.29 | ||||
| - | ||||
| - | ||||
| -1.60 | ||||
| -3.34 | ||||
| -142.15 | ||||
| -0.01 | ||||
| 5.33M | ||||
| Forward PE | -6.16 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.40 | ||||
| 0.90 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | 2.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | - | -0.45 | - |
| Q02 2022 | - | -0.03 | - |
| Q03 2020 | -0.10 | -0.06 | 40.00 |
| Q02 2020 | -0.10 | -0.11 | -10.00 |
| Q01 2020 | -0.17 | -0.08 | 52.94 |
| Q04 2019 | - | -0.32 | - |
| Q03 2019 | -0.32 | -0.14 | 56.25 |
| Q02 2019 | -0.57 | -0.43 | 24.56 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2021 QR | -0.05 | 0.00 | - |
| 12/2021 QR | -0.04 | 20.00 | Positive |
| 12/2021 FY | -0.20 | -300.00 | Negative |
| 12/2022 FY | -0.18 | 14.29 | Positive |
| Next Report Date | 24th Mar 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 89.30K |
| Shares Outstanding | 5.53K |
| Shares Float | 11.99M |
| Trades Count | 145 |
| Dollar Volume | 94.76K |
| Avg. Volume | 619.37K |
| Avg. Weekly Volume | 132.57K |
| Avg. Monthly Volume | 818.82K |
| Avg. Quarterly Volume | 906.74K |
Avenue Therapeutics Inc. (NASDAQ: ATXI) stock closed at 1.05 per share at the end of the most recent trading day (a -0.94% change compared to the prior day closing price) with a volume of 118.46K shares and market capitalization of 5.81M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 4 people. Avenue Therapeutics Inc. CEO is Alexandra MacLean.
The one-year performance of Avenue Therapeutics Inc. stock is -89.14%, while year-to-date (YTD) performance is -9.48%. ATXI stock has a five-year performance of -98.72%. Its 52-week range is between 0.983 and 16.65, which gives ATXI stock a 52-week price range ratio of 0.43%
Avenue Therapeutics Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 14.29, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -870.59%, a ROC of -847.42% and a ROE of 5 775.10%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Avenue Therapeutics Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Avenue Therapeutics Inc.’s next earnings report date is 24th Mar 2023.
The consensus rating of Wall Street analysts for Avenue Therapeutics Inc. is — (0), with a target price of $9, which is +756.74% compared to the current price. The earnings rating for Avenue Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Avenue Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Avenue Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.56, ATR14 : 0.10, CCI20 : -83.66, Chaikin Money Flow : -0.05, MACD : -0.04, Money Flow Index : 77.18, ROC : -0.94, RSI : 40.32, STOCH (14,3) : 10.34, STOCH RSI : 0.03, UO : 45.11, Williams %R : -89.66), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Avenue Therapeutics Inc. in the last 12-months were:
Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company that develops and markets pharmaceutical products for the acute care setting. It focuses on developing its product candidate, an intravenous (IV) formulation of tramadol HCI (IV Tramadol), for post-operative acute pain.
CEO: Alexandra MacLean
Telephone: +1 781 652-4500
Address: 1140 Avenue of the Americas, New York 10036, NY, US
Number of employees: 4
